SK bioscience announced today that SK discovery Vice Chairman Choi Chang-won and Maryland Governor Larry Hogan met on September 20 at the SK Bioscience headquarters in Pangyo, Gyeonggi-do.
This meeting was a place to share the results of vaccine development and production during the COVID-19 pandemic and to discuss future cooperation plans.
SK bioscience has continued research, development, and production cooperation with various global companies and organizations, including Novavax, which is headquartered in Maryland, and has recently succeeded in developing Korea's first COVID-19 vaccine.
On this day, Governor Larry Hogan also had time to visit the research facility where "SKYCovione", Korea's first COVID-19 vaccine, was developed, and listen to the development process.
SKYCovione is a COVID-19 vaccine jointly developed by the Washington University Institute for Protein Design (IPD) and SK Bioscience.
Meanwhile, SKYCovione developed by SK bioscience is currently being used for inoculation in Korea and is preparing for full-scale global supply by applying for UK and EU conditional approval and WHO EUL listing.
